Why Novartis's $9.7 Billion Purchase of The Medicines Company Is Bad News for AmgenThe Motley Fool • 12/02/19
Amgen (AMGN) Up 11.2% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 11/28/19
Healthy New Drug Sales And A Refreshed Pipeline Helping Lundbeck Set A BottomSeeking Alpha • 11/26/19
Amgen Wraps Otezla Takeover — And Other Fallout From BMY's Celgene BuyInvestors Business Daily • 11/21/19
Amgen raises full-year guidance after closing $13.4 billion Otezla acquisitionMarket Watch • 11/21/19
Amgen Is Taking A $2.7 Billion Stake In A Chinese Biotech — Here's WhyInvestors Business Daily • 10/31/19
Amgen Inc. (AMGN) CEO Bob Bradway on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 10/30/19